Insight Molecular Diagnostics Inc.
Moat Score — Insight Molecular Diagnostics Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | iMDx holds nine patent families acquired with Chronix plus a 2025 colorectal cancer detection patent, but its core dd-cfDNA quantification science is not fundamentally novel to the transplant-testing category the way competitors like CareDx and Natera's own IP positions are, leaving a modest rather than dominant intangible position. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | The company claims digital PCR sample economics are more favorable than competitors' methods at low testing volumes, a real but narrow cost edge that depends on continued access to Bio-Rad's instrument platform rather than a structural, owned cost advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | iMDx is out-of-network with all commercial payers and has only a single CMS-reimbursed product (GraftAssureCore at $2,753/result); it is a price-taker dependent on regulatory reimbursement decisions rather than a company that can set its own pricing against entrenched competitors. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Diagnostic test adoption by one hospital or transplant center does not make the test more valuable to the next customer; there is no network effect in iMDx's business model. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Transplant centers that have already integrated an incumbent's testing workflow (CareDx, Natera) face some switching friction, but as the new entrant iMDx benefits little from this dynamic today — if anything, its own products face the switching-cost barrier from the other side. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | With only 58 employees and a single reimbursed product, iMDx has not reached a scale that would deter new entrants or protect its ~$2 billion addressable market from further competitive entry; the space remains open and contested. |